ERBB2 and breast cancer: In this work, the effect of a new candidate immunoliposome combined with trastuzumab was evaluated in spheroids generated from two HER2-positive breast cancer cell lines (MDA-MB-453 and MDA-MB-231) before testing it in vivo.